HOME >> MEDICINE >> NEWS
Study finds new designer drug is potent treatment for chronic myelogenous leukemia

BOSTON--A laboratory study led by researchers at Dana-Farber Cancer Institute has shown that a potent and highly selective therapy for chronic myelogenous leukemia (CML) may ultimately be more effective than Gleevec, the current standard of care. The researchers report in the February issue of Cancer Cell that the new compound, AMN107, is about 20 times more potent than Gleevec and is effective in treating Gleevec-resistant disease in model systems. Discovered by and in development with Novartis Pharma AG, AMN107 is a small molecule tyrosine kinase inhibitor.

"While Gleevec represents a major treatment advance for CML approximately 95 percent of patients treated with Gleevec achieve remission there clearly is a need for therapies that produce longer remissions, are active against advanced disease, and can be used when Gleevec loses effectiveness," says Dana-Farber's James Griffin, MD, senior author of the study.

Gleevec shuts down CML by blocking the function of Bcr-Abl, the abnormal tyrosine kinase protein in the leukemic cells that causes them to grow too quickly. However, it does not bind very tightly to this protein, and patients can develop a resistant type of Bcr-Abl that no longer binds to Gleevec at all.

Using rational drug design to circumvent these shortcomings, researchers at Novartis determined the crystal structure of Bcr-Abl, and then constructed compounds that would lock into the receptor more securely than Gleevec. Investigators at Dana-Farber tested the new compounds to measure their effectiveness against CML in laboratory cell cultures and mice with the disease.

Data from the study published in Cancer Cell showed that in experiments with laboratory samples of CML cells, AMN107 killed the cells more effectively than Gleevec. In follow-up studies with mice with a human form of CML, AMN107 produced lengthier remissions than Gleevec and triggered remissions in animals in which the disease had become resistant to Gl
'"/>

Contact: Bill Schaller
617-632-4090
Dana-Farber Cancer Institute
18-Feb-2005


Page: 1 2

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/16/2019)... ... 2019 , ... Delta County Memorial Hospital (DCMH) has partnered ... increase access to care for rural patients. Delta Montrose Home Health (DMHH) is ... patient monitoring services to the Colorado Western Slope. , Delta Hospital's Home Remote ...
(Date:5/16/2019)... ... May 16, 2019 , ... Enso ... market a patent pending, affordable, effective, easy-to-use, university-validated Platelet Rich Fibrin (PRF) kit ... achievement is a testament to the dedication of the Enso Discoveries team to ...
(Date:5/15/2019)... (PRWEB) , ... May 15, 2019 , ... ... of senior living services in the Northeast, today announced that its founder, chairman ... Lifetime Achievement Award. Grape was honored for his pioneering efforts over the last ...
(Date:5/15/2019)... ... May 16, 2019 , ... Statistical Concepts of Process Validation ... p.m. EDT, https://www.fdanews.com/statisticalconceptsprocessvalidation , Devicemakers: Are the organizations process validation processes ... … Dan O’Leary is here to help. Dan is FDAnews’s go-to guy on ...
(Date:5/15/2019)... (PRWEB) , ... May 15, 2019 , ... ... Gary Stubblefield as Vice President of Healthcare Insurance Strategy. , Stubblefield comes ... roles ranging from community hospital administration to corporate marketing and business development. ...
Breaking Medicine News(10 mins):
(Date:5/16/2019)... ... May 16, 2019 , ... ... announced it has launched Mobile Patient Intake. This new solution helps providers deliver ... process at their own convenience, on their device of choice, days or weeks ...
(Date:5/15/2019)... ... 15, 2019 , ... Claudius Moore, a seasoned technology executive, ... Information Technology. Over the last 15 years, Moore has mastered a method to ... creating a high-quality, efficient experience for patients. , Moore will lead AFC’s information ...
(Date:5/15/2019)... , ... May 15, 2019 , ... Dr. Faye Jamali ... skin care with two results-driven skin care products—Belle Glow Rx and - - ... tone by calming skin and guarding against damaging free radicals with a potent combination ...
Breaking Medicine Technology:
Cached News: